Naguib Sarah S, Hathout Rania M, Mansour Samar
a Department of Pharmaceutical Technology , Faculty of Pharmacy and Biotechnology, German University in Cairo , Cairo , Egypt and.
b Department of Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Ain Shams University , Cairo , Egypt.
Drug Deliv. 2017 Nov;24(1):99-108. doi: 10.1080/10717544.2016.1233588.
Usually the topical delivery of ocular drugs poses a great challenge. Accordingly, the work in this study comprised the use of different hybrids of generally regarded as safe (GRAS) oils and surfactants in order to develop and optimize novel acetazolamide (AZD) entrapped-vesicular systems aiming at improving its ocular delivery and reaching better therapeutic outcomes in the treatment of glaucoma. The phospholipid/cholesterol bilayer of the vesicles was enriched with hybrids of Tween 80, Labrasol, Transcutol and Labrafac lipophile WL in different masses and proportions according to a mixture design viz. D-optimal mixture design. Three models were generated comprising three responses: particles size, percentage of entrapment efficiency and amount of drug released after 24 hours (Q24h). The results demonstrated the ability of the penetration enhancing hybrids in modulating the three responses compared to the conventional liposomes. Transmission electron microscope was used to characterize the selected formulations. Sterilization of selected formulations was carried out using gamma radiation and the effect of gamma radiations on entrapment, particle size and in vitro release were studied. The selected sterilized formulations were tested in-vivo on the eyes of albino rabbits in order to evaluate the efficiency of the novel delivery systems on the intra-ocular pressure reduction (IOP) compared to drug solution and the conventional liposomes. The novel formulations proved their efficiency in reducing the IOP to lower values compared to the conventional liposomes, which pose new successful platform for ocular delivery of AZD and other anti-glaucoma drug analogs.
通常,眼部药物的局部给药面临巨大挑战。因此,本研究的工作包括使用不同的一般认为安全(GRAS)的油和表面活性剂混合物,以开发和优化新型包载乙酰唑胺(AZD)的囊泡系统,旨在改善其眼部给药效果,并在青光眼治疗中取得更好的治疗效果。根据混合设计即D - 最优混合设计,在不同质量和比例下,用吐温80、Labrasol、Transcutol和Labrafac亲脂性WL的混合物丰富囊泡的磷脂/胆固醇双层。生成了三个模型,包含三个响应:粒径、包封率百分比和24小时后释放的药物量(Q24h)。结果表明,与传统脂质体相比,渗透增强混合物有能力调节这三个响应。使用透射电子显微镜对选定的制剂进行表征。使用γ射线对选定的制剂进行灭菌,并研究γ射线对包封、粒径和体外释放的影响。将选定的灭菌制剂在白化兔的眼睛上进行体内测试,以评估新型给药系统与药物溶液和传统脂质体相比在降低眼压(IOP)方面的效率。与传统脂质体相比,新型制剂证明了它们在将眼压降低到更低值方面的有效性,这为AZD和其他抗青光眼药物类似物的眼部给药提供了新的成功平台。